Shares of Pain Therapeutics (NASDAQ:PTIE) saw an uptick in trading volume on Wednesday . 304,102 shares traded hands during trading, an increase of 93% from the previous session’s volume of 157,492 shares.The stock last traded at $2.51 and had previously closed at $2.60.

Separately, Zacks Investment Research raised shares of Pain Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 31st.

The stock’s 50-day moving average is $2.45 and its 200-day moving average is $2.21. The firm’s market capitalization is $115.81 million.

Pain Therapeutics (NASDAQ:PTIE) last released its quarterly earnings results on Tuesday, July 19th. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.07. On average, analysts forecast that Pain Therapeutics will post ($0.42) EPS for the current fiscal year.

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.